NSCLC metastatic/molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 19/01/2023)

AKT mutation
Currently no open trials

ALK fusion
Currently no open trials

BRAF mutation
TAPISTRY (Roche)
Tumor-Agnostic Precision Somatic Targeting for Class II or III BRAF mutation with Belvarafenib. 
(contact datanursingreo@uzleuven.be to check whether one of the cohorts is open)
 
EGFR common exon 19 or exon 21 mutation
FLOSI (Academic) (1st line) 
Local AblativeTherapy for Oligoprogressive EGFRm Non-Small-Cell Lung Cancer Treated on First-line OSImertinib.

MARIPOSA-2 (Janssen) (2nd line) 
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure.

HERTHENA-Lung-02 (Daiichi) (2nd and 3rd line, after TKI failure)
A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy.

EGFR exon 20 insertion mutation
Currently no open trials

HER2 mutation
DESTINY-LUNG04 (Astra Zeneca) (1st line) - exon 19 and 20 mutation
An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

KRAS G12C mutation
JDQ443 A (Novartis) (2nd and 3rd line) Mono or combination therapy.
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation.
(contact datanursingreo@uzleuven.be to check whether one of the cohorts is open)

JDQ443 E (Novartis) (2nd and 3rd line).
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation.
(contact datanursingreo@uzleuven.be to check whether one of the cohorts is open)

BI1823911 (Boehringer) (end-line)
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in Advanced Cancer With KRAS Mutation. 
(contact datanursingreo@uzleuven.be to check whether one of the cohorts is open)

MET
Currently no open trials

NRG1 fusion
MCLA-128-CL01 (Merus) (any line)
A Phase I/II Study of Zenocutuzumab (MCLA-128), a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors.

NTRK fusion
TRIDENT-1 (TurningPoint)  (1st, 2nd and 3rd line)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring NTRK1-3 Rearrangements.

PIK3CA mutation
TAPISTRY (Roche) (1st and 2nd line)
Tumor-Agnostic Precision Somatic Targeting PIK3CA with Inavolisib (GDC-0077).

RET fusion
Currently no open trials

ROS1 fusion
Currently no open trials

3rd line (all mutations)
ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.